Oritinib
Oritinib (SH-1028) is a potent and selective EGFR inhibitor, showing low nanomolar IC50 values against wild-type and various mutant forms, including the resistant T790M variant. It is a research tool for investigating targeted therapies in non-small cell lung cancer, with utility in both in vitro biochemical assays and in vivo preclinical models.
Product Specifications
CAS Number
2035089-28-0
Product Name Alternative
Inhibit, non-small cell lung cancer, Irreversible, mutant-selective, EGFR, EGFR (L858R), EGFR (L858R/T790M), EGFR (L861Q), EGFR (wt), EGFR TKI, EGFR-T790M, Epidermal growth factor receptor, ErbB-1, Inhibitor, HER1, Oritinib, third-generation, pharmacodynamics, SH1028, SH-1028, SH 1028
Field of Research
Cardiovascular Research, Signal Transduction
Purity
98.40% (May vary between batches)
Solubility
DMSO:120 mg/mL (222.36 mM)
Smiles
COc1cc (N (C) CCN (C) C) c (NC (=O) C=C) cc1Nc1nccc (n1) -c1c2CCCCn2c2ccccc12
Molecular Formula
C31H37N7O2
Molecular Weight
539.67
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
